SCHEMBL1025814

SCHEMBL1025814

Cc1ccc2ncc([N+](=O)[O-])c(O)c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.48
KMT2A Q03164 7/20 0.48
MEN1 O00255 6/20 0.48
NPSR1 Q6W5P4 2/20 0.48
MITF O75030 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
GPR35 Q9HC97 3/20 0.46
TSHR P16473 2/20 0.46
CYP3A4 P08684 1/20 0.46
GAA P10253 4/20 0.42
NCOA1 Q15788 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42
POLB P06746 1/20 0.41
ABCC3 O15438 1/20 0.40
ABCC4 O15439 1/20 0.40
NR1I2 O75469 1/20 0.40
ABCB11 O95342 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5767153 0.88 GPR35 (0.46) MAPTKMT2AMEN1NPSR1MITF
SCHEMBL26199343 0.84 MAPT (0.49) MAPTKMT2AMEN1NPSR1MITF
SCHEMBL28028333 0.82 MEN1 (0.40) MAPTKMT2AMEN1SMN1; SMN2GPR35
SCHEMBL1024702 0.82 MAPT (0.47) MAPTKMT2AMEN1NPSR1MITF
SCHEMBL358629 0.82 MAPT (0.45) MAPTKMT2AMEN1SMN1; SMN2TSHR
SCHEMBL2246946 0.82 TDP1 (0.45) MAPTKMT2AMEN1SMN1; SMN2GPR35
SCHEMBL2143638 0.82 MEN1 (0.40) MAPTKMT2AMEN1SMN1; SMN2GPR35
SCHEMBL404980 0.82 TSHR (0.45) MAPTKMT2AMEN1SMN1; SMN2GPR35
SCHEMBL2246907 0.81 LMNA (0.45) MAPTKMT2AMEN1NPSR1SMN1; SMN2
SCHEMBL2246090 0.81 TP53 (0.41) MAPTKMT2AMEN1SMN1; SMN2GPR35

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10039753-B2 Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors PFIZER INC. (US) 2018-08-07 US disclosed
US-20170073343-A1 Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors PFIZER INC. (US) 2017-03-16 US disclosed
US-8637670-B2 Imidazo [4,5-C]quinoline derivatives and their use in the treatment of tumors and/or inflammation Piramal Enterprises Limited (IN) 2014-01-28 US disclosed
EP-2448937-A1 IMIDAZO [4,5-C]QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS AND/OR INFLAMMATION Piramal Life Sciences Limited (IN) 2012-05-09 EP disclosed
US-20120108627-A1 IMIDAZO [4,5-C]QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS AND/OR INFLAMMATION Piramal Enterprises Limited (IN) 2012-05-03 US disclosed
WO-2011001212-A1 IMIDAZO [4,5-C]QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS AND/OR INFLAMMATION PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-01-06 WO disclosed
US-7148232-B2 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-12-12 US disclosed
EP-1380587-B1 Oxazolo, thiazolo and selenazolo [4,5-c]naphthyridine-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES CO (US) 2006-03-15 EP disclosed
US-20050026943-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2005-02-03 US disclosed
US-6809203-B2 IMMUNOMODULATORS; INDUCING CYTOKINE BIOSYNTHESIS INCLUDING INTERFERON-ALPHA AND/OR TUMOR NECROSIS FACTOR-ALPHA 3M INNOVATIVE PROPERTIES COMPANY 2004-10-26 US disclosed
US-20030065006-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2003-04-03 US disclosed
US-20030064968-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2003-04-03 US disclosed
US-20030045545-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2003-03-06 US disclosed
US-6440992-B1 ARE IMMUNOMODULATORS AND INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR, AND INHIBIT T-HELPER-TYPE 2 IMMUNE RESPONSE; USEFUL FOR THERAPY OF VIRAL AND NEOPLASTIC DISEASES 3M INNOVATIVE PROPERTIES COMPANY 2002-08-27 US disclosed
US-20020072528-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2002-06-13 US disclosed
US-6323200-B1 THE COMPOUNDS ARE IMMUNOMODULATORS AND INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR, AND INHIBIT THE T-HELPER-TYPE 2 IMMUNE RESPONSE. 3M INNOVATIVE PROPERTIES COMPANY 2001-11-27 US disclosed
CN-1320126-A Oxazolo, thiazolo and selenazolo [4, 5-C ] quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES CO (US) 2001-10-31 CN disclosed
EP-1100802-A1 OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF 3M Innovative Properties Company (US) 2001-05-23 EP disclosed
US-6110929-A IMMUNOMODULATORS WHICH INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR AND INHIBIT T-HELPER-TYPE 2 IMMUNE RESPONSE; FOR TREATMENT OF VIRAL AND NEOPLASTIC DISEASES 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-08-29 US disclosed
WO-2000006577-A1 OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170073343-A1 Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors LRRK2, PARK7, SNCA MAPT 285/4885KMT2A 499/4885MEN1 1528/4885
US-20030064968-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 MAPT 3980/4885KMT2A 2482/4885MEN1 3773/4885
US-20020072528-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 MAPT 3980/4885KMT2A 2482/4885MEN1 3773/4885
US-10039753-B2 Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors LRRK2, PARK7, SNCA MAPT 246/4885KMT2A 365/4885MEN1 1416/4885
US-20030065006-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 MAPT 3980/4885KMT2A 2482/4885MEN1 3773/4885
US-20050026943-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, IL2, IRF3 MAPT 3413/4885KMT2A 2907/4885MEN1 2840/4885
US-20120108627-A1 IMIDAZO [4,5-C]QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS AND/OR INFLAMMATION IL6, RPS6KA6, MTOR MAPT 3264/4885KMT2A 4290/4885MEN1 4380/4885
US-20030045545-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 MAPT 3980/4885KMT2A 2482/4885MEN1 3773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.